Oral form of Remodulin approved

Share this article:

United Therapeutics said Friday that the FDA approved Orenitram (treprostinil), its oral formulation of pulmonary arterial hypertension treatment Remodulin (treprostinil). The agency sanctioned the extended-release tablets for treating PAH in WHO Group I patients to improve exercise capacity.

The FDA had rejected the drug twice before, once in October 2012 and again this past March. In response to the second CRL, the company resubmitted the drug in September, and at the time the firm said that the new PDUFA date was February 2014.

In its statement Friday, the company said the drug confers a "small" treatment effect. In one study, FREEDOM-M, patients on Orenitram twice daily improved their median six-minute walk distance by +23 meters as compared to patients receiving only placebo. Two other Phase III studies did not demonstrate a benefit.

On a conference call this morning, according to a recap from ISI Group analyst Mark Schoenebaum, management said it will launch the drug in the next six months and that it will be distributed through the same specialty pharmacies as its other PAH drugs, Remodulin and Tyvaso, which is an inhaled version of the same active ingredient as that of Remodulin and Orenitram.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Novartis apologizes for slow reporting

Novartis is apologizing to Japan after the Ministry of Health, Labor and Welfare said the company had dragged its feet reporting adverse events for two of its cancer drugs.

J&J pulls morcellator from market

The company is calling the move a withdrawal, as opposed to a recall.

Pfizer buys two Baxter vaccines

The meningitis and encephalitis medications earned a combined $300 million last year.